Last Updated: November 8, 2026

EPI E Z PEN JR Drug Patent Profile

« Back to Dashboard


When do Epi E Z Pen Jr patents expire, and what generic alternatives are available?

Epi E Z Pen Jr is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in EPI E Z PEN JR is epinephrine. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Epi E Z Pen Jr

A generic version of EPI E Z PEN JR was approved as epinephrine by BPI LABS on July 29th, 2014.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EPI E Z PEN JR?
  • What are the global sales for EPI E Z PEN JR?
  • What is Average Wholesale Price for EPI E Z PEN JR?
Summary for EPI E Z PEN JR

US Patents and Regulatory Information for EPI E Z PEN JR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris EPI E Z PEN JR epinephrine INJECTABLE;INTRAMUSCULAR 019430-004 Aug 3, 1995 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for EPI E Z PEN JR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3678649 LUC00378 Luxembourg ⤷  Start Trial PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649 2025C/508 Belgium ⤷  Start Trial PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.